Caring for adult children with cancer: 4 tips for parents mdanderson.org/cancerwise/car…

Dr Goff on the Investigation of Adjuvant Atezolizumab Plus Bevacizumab in HCC onclive.com/view/dr-goff-o… via onclive

What happens if a doctor finds cancer during my colonoscopy? Read here to find out: mdanderson.org/cancerwise/wha…

RT timnewhook19: 🔥💥🔥💥🔥

RT ColonCancerDoc: That’s 1:4 patients with rectal cancer and 1:10 patients with colon cancer (doi:10.1001/jamasurg.2014.1756). Get #CRC s…

RT Aiims1742: Last night I had a chance to read the comments on the nytimes article on the #PancreaticCancer vaccine trial. Agnostic to t…

RT curecc: When you donate, you become an integral part of our championing collaborative efforts and research that lead to new treatments…

RT MDAndersonNews: "I didn’t stop fighting or seeking answers, and that led us to MD Anderson," says Luke Miller. Learn his story here:…

RT lustgartenfdn: Congratulations Karyn Goodman, MD, MS & Rebecca Snyder, MD, MPH, 2023 recipients of the Lustgarten Equity, Accessibility…

RT CrcTrialsChat: If you missed yesterday's #CRCTrialsChat session on Immune Checkpoint Inhibitors & Combinations for #MSS Stage IV #CRC ,…

RT MDAndersonNews: Our experts will present their latest research at #ASCO23, including studies of acute lymphoblastic leukemia, KRAS G12C…

We are delighted to have you join GI Med Onc faculty at MD Anderson Cancer Center and be able to continue the great work you have started with Christine Parseghian, MD and others!

A well laid out thread on barriers for PS trainees and the “cliff” after ending formal training, among other barriers. Really highlights the key issues.

A nice overview from our talented Dr Fangman and Kanwal Raghav 🩺 🖖🏻. Worth a read for updates on the rapidly moving field.

Precemtabart tocentecan, an anti-CEACAM5 ADC, is active in heavily pretreated metastatic colorectal cancer—median PFS is 6.9 months, and 72% disease control at 12 weeks. First CRC cohort reported in Nature Medicine. #crcsm

Updated precemtabart tocentecan (M9140, CEACAM ADC) data in mCRC presented at ASCO '25: 31% response rate and mPFS of 6.9m in 100% irinotecan pretreated patients. ADCs can overcome TOP1 relative resistance. ascopubs.org/doi/10.1200/JC… #crcsm

Delighted to visit National Cancer Center Hospital East In Tokyo and connect with dear colleagues. Wonderful updates from SCRUM and MONSTAR program, led by Takayuki Yoshino and kindly hosted by Dr. Bando. Looking forward to more collaborations on MRD! #crcsm

Important team finding: Fusions occur in 1.3% of mCRC w/ focused partner-agnostic ctDNA assay, but vast majority are subclonal after EGFRi and likely wouldn't provide meaningful benefit if targeted. Keep hunting for the very rare clonal fusions for clinical benefit!

Targeting the YAP-SDC1 axis overcomes resistance to KRASi in GI cancers by blocking SDC1-driven macropinocytosis and RTK activation, offering a promising strategy for KRASi resistance. Wantong Yao Haoqiang Ying Cell Reports Medicine #crcsm To the clinic! pubmed.ncbi.nlm.nih.gov/40713971/

INTERCEPT MRD study: TAS-102 cleared ctDNA in 5/15 (33%) CRC pts with MRD at 6mo, vs 2/30 (7%) in controls, with median DFS to 9.4mo vs 5.8mo. Durable? Scott Kopetz, @kanwal_Raghav, Ryan Huey, MD, MS, christine Parseghian 71, Michael Overman, maria pia morelli, Arvind Dasari, MD, MS. #crcsm MD Anderson Cancer Center